首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷分子呈像/呈影劑

市場調查報告書

商品編碼

1866535

造影注射器市場－2025-2030年預測

Contrast Injector Market - Forecasts from 2025 to 2030

出版日期: 2025年11月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

造影注射器市場預計將從 2025 年的 15.56 億美元成長到 2030 年的 22.06 億美元，複合年成長率為 7.24%。

造影注射器市場是醫學影像領域的基礎性組成部分，它能夠精準地注射造影劑，從而提高CT、MRI和血管造影術等檢查的影像清晰度。這些自動化系統可以控制造影劑的用量，最大限度地降低風險，並最佳化放射科、介入心臟科和神經科的診斷效果。在影像檢查和技術融合的推動下，以及醫療界對慢性疾病早期檢測日益重視的推動下，該市場持續擴張。然而，高成本和複雜的監管環境正在限制其成長，尤其是在新興地區。

本分析檢驗了當前及近期需求、供應和銷售趨勢，深入分析了促進因素、阻礙因素和機遇，包括區域政策和法規。它分析了以FDA和EMA等監管機構為主導的監管環境，並指出了影響市場動態的因素。

我們的競爭情報分析主要企業及其對營收的影響。分析基於二手資料研究，涵蓋協會調查、分析師報告、投資者報告、新聞稿和學術期刊。我們的市場規模估算採用由下而上和自上而下相結合的方法，並輔以價值鏈相關人員的意見。我們的市場分析整合了多個數據來源和專有數據，從而建立穩健的分析和預測。

透過敘述、圖表和圖形來傳達洞察，以便更清晰地了解市場。 2024年，該市值約為20.8億美元，預計2025年將達22.4億美元，到2030年將成長至37.5億美元，複合年成長率為10.87%。主要細分市場包括注射器系統（單頭、雙頭、無針注射器）和耗材，其中放射學應用佔據主導地位，2024年市場佔有率將達到45.47%。

主要亮點

慢性疾病（包括心血管疾病和癌症）的日益增多，推動了對使用造影進行診斷影像的需求。非傳染性疾病（NCDs）佔全球死亡人數的71%。具備劑量最佳化功能的AI驅動注射器可提高安全性和效率。預計到2050年，65歲以上人口將達到15億，老齡化人口將隨之增加，診斷需求也隨之增加。然而，高昂的設備成本（高級型號超過5萬美元）限制了其在資源匱乏地區的普及應用。

成長要素

慢性病流行（每年有1790萬人死於心血管疾病）導致人們對診斷影像的依賴性日益增強。人工智慧預測劑量等創新技術（可減少20%的浪費）將簡化工作流程。人口結構變化將推動檢查量增加，預計到2024年，老年影像檢查量將增加12%。微創手術量到2025年將成長15%，這需要精準的輸液設備。

抑制因素

高昂的實施和維修成本是廣泛應用的一大障礙，尤其是在低收入地區，超過50%的患者無法獲得放射科服務。嚴格的FDA/EMA核准流程延緩了產品上市，而造影劑造影的風險，例如腎毒性，進一步加劇了這個問題。發展中地區基礎設施的匱乏也限制了其應用。

細分分析

按產品類型分類：注射器系統因其與CT/MRI的兼容性主導。與頻繁操作相關的耗材將成為成長最快的產品。

按技術分類：旨在減少錯誤並整合人工智慧的自動注射器是主流，佔市場佔有率的 60% 以上。

按應用領域分類：放射科佔 45.47%，這主要歸因於 CT/MRI 檢查的激增，介入性心臟病學也在加速發展。

按最終用戶分類：醫院和診所佔 68.37%，這得益於基礎設施投資。

區域分析

北美地區將持續保持領先地位，預計2024年將佔據38.87%的市場。在慢性病負擔日益加重和技術創新推動下，預計到2025年，北美市場規模將達到8.7249億美元（年複合成長率為9.69%）。亞太地區將成為成長最快的地區，年複合成長率為8.5%，主要得益於中國和印度醫療保健產業的擴張。歐洲市場將因人口老化和監管支持而保持穩定成長。

重大進展

2025 年初，GE 醫療與一家人工智慧公司合作開發了一種具有預測分析功能的注射器，用於個人化 CT/血管造影術的藥物劑量；2024 年，Bracco 推出了環保型「Max 3™」無針 MRI 注射器，透過可回收組件減少廢棄物。

本報告為專業人士提供了關於趨勢、法規和競爭格局的實用見解，重點闡述了人工智慧和永續性領域在成本壁壘下所蘊含的機會。報告採用基於一手和二手數據的嚴謹調查方法，得出可靠的預測，為投資決策提供支持，而投資決策對於該領域的診斷至關重要。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2022-2024 年）和預測資料（2025-2030 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

介紹
北美洲
- 按噴油器類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 按噴油器類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 按噴油器類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 英國
  - 德國
  - 法國
  - 義大利
  - 其他
中東和非洲
- 按噴油器類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 其他
亞太地區
- 按噴油器類型
- 透過使用
- 最終用戶
- 按國家/地區
  - 日本
  - 中國
  - 印度
  - 韓國
  - 台灣
  - 其他

第9章：競爭格局與分析

主要企業和策略分析
市佔率分析
企業合併、協議、商業合作
競爭對手儀錶板

第10章：公司簡介

Bayer AG
Bracco Imaging SpA
Guerbet SA
Medtron AG
Ulrich GmbH & Co. KG
GE Healthcare
Nemoto Kyorindo Co., Ltd.
Medtronic plc
AngioDynamics, Inc.
Hilin Life Products, Inc.
Apollo RT Co. Ltd.
Vivid Imaging
Sino Medical-Device Technology Co., Ltd.

第11章分析方法

簡介目錄

Product Code: KSI061611961

The Contrast Injector Market is expected to grow from USD 1.556 billion in 2025 to USD 2.206 billion in 2030, with a 7.24% CAGR.

The contrast injector market is a cornerstone of medical imaging, facilitating precise administration of contrast agents to enhance visibility in CT, MRI, and angiography procedures. These automated systems deliver controlled volumes of media, minimizing risks and optimizing diagnostic outcomes in radiology, interventional cardiology, and neurology. With healthcare's emphasis on early detection of chronic conditions, the market is expanding, propelled by rising imaging volumes and technological integration. However, high costs and regulatory complexities temper growth, particularly in emerging regions.

This analysis explores current demand, supply, and sales trends, alongside recent developments. It delivers a thorough examination of drivers, restraints, and opportunities, including regional policies and regulations. The regulatory landscape, governed by bodies like the FDA and EMA, is dissected to illuminate factors shaping market dynamics.

Competitive intelligence profiles key players and their revenue impacts, sourced from secondary research encompassing association studies, analyst reports, investor materials, press releases, and journals. Market sizing for the sector and segments employs bottom-up and top-down methods, corroborated by stakeholder inputs from the value chain. Market engineering consolidates multi-source data and proprietary datasets via triangulation for robust breakdowns and projections.

Insights are conveyed through narratives, charts, and graphics for streamlined market comprehension. The market, valued at approximately USD 2.08 billion in 2024, is projected to reach USD 2.24 billion in 2025, growing at a CAGR of 10.87% to USD 3.75 billion by 2030. Key segments include injector systems (single-head, dual-head, syringeless) and consumables, with radiology applications dominating at 45.47% share in 2024.

Key Highlights

Rising chronic diseases, including cardiovascular conditions and cancer, escalate demand for contrast-enhanced imaging, with NCDs causing 71% of global deaths. AI-driven injectors with dose optimization boost safety and efficiency. An aging population, projected to hit 1.5 billion over 65 by 2050, heightens diagnostic needs. High equipment costs, exceeding $50,000 for advanced models, constrain adoption in resource-limited settings.

Growth Drivers

Chronic disease prevalence, with cardiovascular issues claiming 17.9 million lives yearly, drives imaging reliance. Technological innovations, like AI for predictive dosing reducing waste by 20%, streamline workflows. Demographic shifts amplify procedure volumes, with a 12% rise in elderly imaging noted in 2024. Minimally invasive procedures, up 15% in 2025, favor precise injectors.

Restraints

Elevated costs for acquisition and maintenance hinder penetration, especially in low-income areas where over 50% lack radiology services. Stringent FDA/EMA approvals delay launches, compounded by contrast-related risks like nephrotoxicity. Infrastructure deficits in developing regions limit access.

Segmentation Analysis

By Product: Injector systems lead, driven by CT/MRI compatibility; consumables grow fastest with high procedure volumes.

By Technology: Automated injectors prevail for error reduction and AI integration, holding over 60% share.

By Application: Radiology commands 45.47% due to CT/MRI surges, with interventional cardiology accelerating.

By End-User: Hospitals & clinics dominate at 68.37%, fueled by infrastructure investments.

Regional Analysis

North America leads with 38.87% share in 2024, bolstered by chronic disease burdens and innovations, projecting USD 872.49 million in 2025 at 9.69% CAGR. Asia Pacific grows fastest at 8.5% CAGR, driven by healthcare expansions in China and India. Europe sustains steady growth via aging demographics and regulatory support.

Key Developments

In early 2025, GE HealthCare partnered with an AI firm for predictive analytics-enabled injectors, personalizing CT/angiography dosing. In 2024, Bracco launched the eco-friendly Max 3(TM) syringeless MRI injector, reducing waste via recyclable components.

This report arms experts with actionable intelligence on trends, regulations, and competition. It spotlights opportunities in AI and sustainability amid cost hurdles. Methodological rigor from primary/secondary data yields dependable projections, aiding navigation of investments in this diagnostics linchpin.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2022 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Injector Type

Single-Head Injector
Dual-Head Injectors
Syringeless Injector

By Application

Radiology
Intervention radiology
Intervention cardiology

By End-User

Hospitals & Clinics
Diagnostic Centres
Ambulatory Surgical Centres
Clinics and Research Institutes

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Italy
Others
Middle East & Africa
Saudi Arabia
UAE
Others
Asia Pacific
Japan
China
India
South Korea
Taiwan
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CONTRAST INJECTOR MARKET BY INJECTOR TYPE

5.1. Introduction
5.2. Single-Head Injector
5.3. Dual-Head Injectors
5.4. Syringeless Injector

6. CONTRAST INJECTOR MARKET BY APPLICATION

6.1. Introduction
6.2. Radiology
6.3. Intervention radiology
6.4. Intervention cardiology

7. CONTRAST INJECTOR MARKET BY END-USER

7.1. Introduction
7.2. Hospitals & Clinics
7.3. Diagnostic Centres
7.4. Ambulatory Surgical Centres
7.5. Clinics and Research Institutes

8. CONTRAST INJECTOR MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. By Injector Type
- 8.2.2. By Application
- 8.2.3. By End-User
- 8.2.4. By Country
  - 8.2.4.1. United States
  - 8.2.4.2. Canada
  - 8.2.4.3. Mexico
8.3. South America
- 8.3.1. By Injector Type
- 8.3.2. By Application
- 8.3.3. By End-User
- 8.3.4. By Country
  - 8.3.4.1. Brazil
  - 8.3.4.2. Argentina
  - 8.3.4.3. Others
8.4. Europe
- 8.4.1. By Injector Type
- 8.4.2. By Application
- 8.4.3. By End-User
- 8.4.4. By Country
  - 8.4.4.1. United Kingdom
  - 8.4.4.2. Germany
  - 8.4.4.3. France
  - 8.4.4.4. Italy
  - 8.4.4.5. Others
8.5. Middle East & Africa
- 8.5.1. By Injector Type
- 8.5.2. By Application
- 8.5.3. By End-User
- 8.5.4. By Country
  - 8.5.4.1. Saudi Arabia
  - 8.5.4.2. UAE
  - 8.5.4.3. Others
8.6. Asia Pacific
- 8.6.1. By Injector Type
- 8.6.2. By Application
- 8.6.3. By End-User
- 8.6.4. By Country
  - 8.6.4.1. Japan
  - 8.6.4.2. China
  - 8.6.4.3. India
  - 8.6.4.4. South Korea
  - 8.6.4.5. Taiwan
  - 8.6.4.6. Others